Synthesis and quantitative structure-activity relationship of hydrazones of N-amino-N'-hydroxyguanidine as electron acceptors for xanthine oxidase.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2004-05-08

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/JM031127CPMID 15163191
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The novel guanidine ME10092 protects the heart during ischemia-reperfusion.

  2002cited by this paper
• Allopurinol neurocardiac protection trial in infants undergoing heart surgery using deep hypothermic circulatory arrest.

  2001cited by this paper
• Methylene blue abolishes aortal tone impairment induced by liver ischemia-reperfusion in a dose response manner: an isolated-perfused double-organ rat model study.

  2001cited by this paper
• N-Hydroxyguanidine compound 1-(3,4-dimethoxy- 2-chlorobenzylideneamino)-3-hydroxyguanidine inhibits the xanthine oxidase mediated generation of superoxide radical.

  2000cited by this paper
• GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors.

  2000cited by this paper
• Amelioration of ischemia-reperfusion injury in rat intestine by pentoxifylline-mediated inhibition of xanthine oxidase.

  1999cited by this paper
• Cardioprotective effects of N‐hydroxyguanidine PR5 in myocardial ischaemia and reperfusion in rats

  1999cited by this paper
• Characterization of the enzymatic activity for biphasic competition by guanoxabenz (1-(2,6-dichlorobenzylidene-amino)-3-hydroxyguanidine) at alpha2-adrenoceptors. II. Description of a xanthine-dependent enzymatic activity in spleen cytosol.

  1998cited by this paper
• Identification of an N-hydroxyguanidine reducing activity of xanthine oxidase.

  1998cited by this paper
• Methylene blue prevents pulmonary injury after intestinal ischemia-reperfusion.

  1998cited by this paper
• Adenosine Deaminase Inhibition Prevents Free Radical-mediated Injury in the Postischemic Heart (*)

  1996cited by this paper
• Role of xanthine oxidase and its inhibitor in hypoxia: reoxygenation injury.

  1996cited by this paper
• Improvement of Cardiac Function by Allopurinol in Patients Undergoing Cardiac Surgery

  1995cited by this paper
• A re-evaluation of the tissue distribution and physiology of xanthine oxidoreductase

  1994cited by this paper
• Design and discovery of new drugs by stepping-up and stepping-down approaches.

  1993cited by this paper
• Synthesis and anti-HIV-1 activity of N-hydroxy-N1-aminoguanidines.

  1992cited by this paper
• Methylene blue as an inhibitor of superoxide generation by xanthine oxidase. A potential new drug for the attenuation of ischemia/reperfusion injury.

  1991cited by this paper
• Reductive activation of potential antitumor bis(aziridinyl)benzoquinones by xanthine oxidase: competition between oxygen reduction and quinone reduction.

  1990cited by this paper
• Evaluation of the role of xanthine oxidase in myocardial reperfusion injury.

  1990cited by this paper
• Design, synthesis, testing, and quantitative structure-activity relationship analysis of substituted salicylaldehyde Schiff bases of 1-amino-3-hydroxyguanidine tosylate as new antiviral agents against coronavirus.

  1990cited by this paper
• The kinetics of 1-nitropyrene and 3-nitrofluoranthene metabolism using bovine liver xanthine oxidase.

  1990cited by this paper
• Reperfusion injury.

  1988cited by this paper
• Oxygen-derived free radicals in postischemic tissue injury.

  1985cited by this paper
• A computational procedure for determining energetically favorable binding sites on biologically important macromolecules.

  1985cited by this paper
• Optimization of the Schiff bases of N-hydroxy-N'-aminoguanidine as anticancer and antiviral agents.

  1985cited by this paper
• Novel N-hydroxyguanidine derivatives as anticancer and antiviral agents.

  1984cited by this paper
• Nitroimidazoles as anaerobic electron acceptors for xanthine oxidase.

  1982cited by this paper
• Tight binding inhibitors of xanthine oxidase.

  1981cited by this paper
• [A clinical trial of guanoxabenz: a hypotensive agent with central and hypertensive action (author's transl)].

  1981cited by this paper
• Susceptibility of aromatic nitro compounds to xanthine oxidase-catalyzed reduction.

  1978cited by this paper

• Recent Applications of the Multicomponent Synthesis for Bioactive Pyrazole Derivatives

  2022cites this paper
• Chemoinformatics and QSAR

  2021cites this paper
• Actions of Inonotus obliquus against Hyperuricemia through XOD and Bioactives Screened by Molecular Modeling

  2018cites this paper
• Toward an Understanding of Structural Insights of Xanthine and Aldehyde Oxidases: An Overview of their Inhibitors and Role in Various Diseases

  2018cites this paper
• Applications of QSAR Study in Drug Design

  2017cites this paper
• 16 Novel Therapeutic Strategies for Chagas ` Disease

  2017cites this paper
• O‑烷基‑苯亚甲基胍衍生物及其治疗与错误折叠蛋白质累积有关疾病的治疗用途

  2015cites this paper
• O-alkyl-benzylideneguanidine derivatives and therapeutic use for the treatment of disorders associated an accumulation of misfolded proteins

  2015cites this paper
• Microwave solid phase synthesis, characterization, and antimicrobial activity of 3,5-diiodo-salicylalidene-glycine-cobalt(II)

  2013cites this paper
• Fatty Acids in Heterocyclic Synthesis Part XII: Synthesis of Surfactants from Pyrazole, Isoxazole, Pyrimidine and Triazine, Incorporating the 1,3,4-Thiadiazole Moiety Having Dyeing and Antimicrobial Activities

  2012cites this paper
• Screening of Potential anti-Trypanosoma cruzi Candidates: In Vitro and In Vivo Studies

  2011cites this paper
• Novel Therapeutic Strategies for Chagas` Disease

  2011cites this paper
• Two dinuclear Schiff-base complexes: synthesis, characterization, and biological activity

  2011cites this paper
• Synthesis, characterization, and antimicrobial activities of a dinuclear copper(II) complex with bis(2-[(2-hydroxy-ethylimino)-methyl]-4,6-diiodo-phenol)

  2011cites this paper
• Xanthine oxidase inhibitors: a patent survey

  2011cites this paper
• In Vitro and In Vivo Activities of 1,3,4-Thiadiazole-2-Arylhydrazone Derivatives of Megazol against Trypanosoma cruzi (cid:1)

  2010cites this paper
• Design, Synthesis, and Pharmacological Investigation of Iodined Salicylimines, New Prototypes of Antimicrobial Drug Candidates

  2010cites this paper
• A comparative study of AutoDock and PMF scoring performances, and SAR of 2-substituted pyrazolotriazolopyrimidines and 4-substituted pyrazolopyrimidines as potent xanthine oxidase inhibitors

  2010cites this paper
• In Vitro and In Vivo Activities of 1,3,4-Thiadiazole-2-Arylhydrazone Derivatives of Megazol against Trypanosoma cruzi

  2010cites this paper
• Synthesis and antibacterial activities of copper(II) with [(2-hydroxy-3,5-diiodo-benzylidene)-amino]-acetic acid

  2010cites this paper
• Synthesis and antimicrobial activities of metal(II) complexes with 2,4-diiodo-6-phenyliminomethyl-phenol

  2010cites this paper
• Synthesis and antibacterial activities of metal(II) complexes with Schiff bases derived from 3,5-diiodosalicylaldehyde

  2009cites this paper
• Synthesis and antimicrobial activities of metal(II) complexes with bis(2,4-diiodo-6-propyliminomethyl-phenol)-pyridine

  2009cites this paper
• Synthesis of Benzo[b]thiophene Carboxamides Connected to 4‐Arylpiperazines through a Benzylic Spacer: Potential Ligands with 5‐HT1A Binding Affinity

  2007cites this paper
• Synthesis of mono- and symmetrical di-N-hydroxy- and N-aminoguanidines.

  2006cites this paper
• Development and applications of new 3D molecular descriptors

  2005cites this paper
• In vivo measurements of the cerebral perfusion and cardiovascular effects of the novel guanidine ME10092 in the non-human primate, Papio ursinus.

  2004cites this paper
• Synthesis and antitrypanosomal profile of new functionalized 1,3,4-thiadiazole-2-arylhydrazone derivatives, designed as non-mutagenic megazol analogues.

  2004cites this paper